Hemab Therapeutics Holdings, Inc. - Common Stock (COAG)

Hemab Therapeutics (NASDAQ:COAG) has launched a pivotal Phase 3 trial of its experimental bleeding-disorder treatment sutacimig, moving its lead program into late-stage development as it prepares additional data presentations in December and February. On the company’s third-quarter earnings call, C

Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build “a multiple product